The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Seliciclib     (2R)-2-[[6-(benzylamino)-9- propan-2-yl...

Synonyms: Rosco, roscovitine, R-Roscovitine, CYC-202, CHEMBL14762, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Seliciclib


High impact information on Seliciclib


Chemical compound and disease context of Seliciclib


Biological context of Seliciclib


Anatomical context of Seliciclib


Associations of Seliciclib with other chemical compounds


Gene context of Seliciclib


Analytical, diagnostic and therapeutic context of Seliciclib


  1. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. Pippin, J.W., Qu, Q., Meijer, L., Shankland, S.J. J. Clin. Invest. (1997) [Pubmed]
  2. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Raje, N., Kumar, S., Hideshima, T., Roccaro, A., Ishitsuka, K., Yasui, H., Shiraishi, N., Chauhan, D., Munshi, N.C., Green, S.R., Anderson, K.C. Blood (2005) [Pubmed]
  3. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Mgbonyebi, O.P., Russo, J., Russo, I.H. Cancer Res. (1999) [Pubmed]
  4. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Whittaker, S.R., Walton, M.I., Garrett, M.D., Workman, P. Cancer Res. (2004) [Pubmed]
  5. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Tirado, O.M., Mateo-Lozano, S., Notario, V. Cancer Res. (2005) [Pubmed]
  6. Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments. Ackerley, S., Thornhill, P., Grierson, A.J., Brownlees, J., Anderton, B.H., Leigh, P.N., Shaw, C.E., Miller, C.C. J. Cell Biol. (2003) [Pubmed]
  7. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Meijer, L., Raymond, E. Acc. Chem. Res. (2003) [Pubmed]
  8. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. Nelson, P.J., Gelman, I.H., Klotman, P.E. J. Am. Soc. Nephrol. (2001) [Pubmed]
  9. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. Schang, L.M., Rosenberg, A., Schaffer, P.A. J. Virol. (2000) [Pubmed]
  10. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Ribas, J., Boix, J., Meijer, L. Exp. Cell Res. (2006) [Pubmed]
  11. Inhibition of DNA synthesis in human gliomas by roscovitine. Yakisich, J.S., Boethius, J., Lindblom, I.O., Wallstedt, L., Vargas, V.I., Sidén, A., Cruz, M.H. Neuroreport (1999) [Pubmed]
  12. Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis. Park, S.S., Eom, Y.W., Choi, K.S. Biochem. Biophys. Res. Commun. (2005) [Pubmed]
  13. Wee1-regulated apoptosis mediated by the crk adaptor protein in Xenopus egg extracts. Smith, J.J., Evans, E.K., Murakami, M., Moyer, M.B., Moseley, M.A., Woude, G.V., Kornbluth, S. J. Cell Biol. (2000) [Pubmed]
  14. Control of in vitro organogenesis by cyclin-dependent kinase activities in plants. Yamaguchi, M., Kato, H., Yoshida, S., Yamamura, S., Uchimiya, H., Umeda, M. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  15. Regulation of NMDA receptors by cyclin-dependent kinase-5. Li, B.S., Sun, M.K., Zhang, L., Takahashi, S., Ma, W., Vinade, L., Kulkarni, A.B., Brady, R.O., Pant, H.C. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  16. Mitotic clonal expansion: a synchronous process required for adipogenesis. Tang, Q.Q., Otto, T.C., Lane, M.D. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  17. Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-RasV12. Shuman, J.D., Sebastian, T., Kaldis, P., Copeland, T.D., Zhu, S., Smart, R.C., Johnson, P.F. Mol. Cell. Biol. (2004) [Pubmed]
  18. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Chen, S., Xu, Y., Yuan, X., Bubley, G.J., Balk, S.P. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  19. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Alvi, A.J., Austen, B., Weston, V.J., Fegan, C., MacCallum, D., Gianella-Borradori, A., Lane, D.P., Hubank, M., Powell, J.E., Wei, W., Taylor, A.M., Moss, P.A., Stankovic, T. Blood (2005) [Pubmed]
  20. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Mohapatra, S., Chu, B., Wei, S., Djeu, J., Epling-Burnette, P.K., Loughran, T., Jove, R., Pledger, W.J. Cancer Res. (2003) [Pubmed]
  21. Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. Krude, T. J. Biol. Chem. (2000) [Pubmed]
  22. S phase progression is required for transcriptional activation of the beta-phaseolin promoter. Chandrasekharan, M.B., Li, G., Bishop, K.J., Hall, T.C. J. Biol. Chem. (2003) [Pubmed]
  23. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. Lin, H., Juang, J.L., Wang, P.S. J. Biol. Chem. (2004) [Pubmed]
  24. A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1). Alevizopoulos, K., Catarin, B., Vlach, J., Amati, B. EMBO J. (1998) [Pubmed]
  25. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. MacCallum, D.E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D.P., Green, S.R. Cancer Res. (2005) [Pubmed]
  26. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Fleming, I.N., Hogben, M., Frame, S., McClue, S.J., Green, S.R. Clin. Cancer Res. (2008) [Pubmed]
  27. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Dey, A., Wong, E.T., Cheok, C.F., Tergaonkar, V., Lane, D.P. Cell Death Differ. (2008) [Pubmed]
  28. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Maggiorella, L., Deutsch, E., Frascogna, V., Chavaudra, N., Jeanson, L., Milliat, F., Eschwege, F., Bourhis, J. Cancer Res. (2003) [Pubmed]
  29. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. Tang, L., Li, M.H., Cao, P., Wang, F., Chang, W.R., Bach, S., Reinhardt, J., Ferandin, Y., Galons, H., Wan, Y., Gray, N., Meijer, L., Jiang, T., Liang, D.C. J. Biol. Chem. (2005) [Pubmed]
  30. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. Gherardi, D., D'Agati, V., Chu, T.H., Barnett, A., Gianella-Borradori, A., Gelman, I.H., Nelson, P.J. J. Am. Soc. Nephrol. (2004) [Pubmed]
WikiGenes - Universities